| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 101 | 2024 | 2585 | 9.120 |
Why?
|
| Shock, Septic | 42 | 2024 | 769 | 5.010 |
Why?
|
| Emergency Service, Hospital | 113 | 2024 | 7873 | 4.560 |
Why?
|
| Microcirculation | 19 | 2024 | 1272 | 3.340 |
Why?
|
| Fluid Therapy | 18 | 2024 | 577 | 3.130 |
Why?
|
| Syncope | 16 | 2019 | 428 | 2.820 |
Why?
|
| Multiple Organ Failure | 12 | 2017 | 387 | 2.750 |
Why?
|
| Hospital Mortality | 61 | 2024 | 5292 | 2.630 |
Why?
|
| Lactic Acid | 18 | 2018 | 1139 | 1.960 |
Why?
|
| Resuscitation | 20 | 2023 | 672 | 1.750 |
Why?
|
| Glycocalyx | 4 | 2024 | 97 | 1.650 |
Why?
|
| Critical Illness | 21 | 2024 | 2709 | 1.510 |
Why?
|
| Systemic Inflammatory Response Syndrome | 13 | 2020 | 619 | 1.480 |
Why?
|
| Hospitalization | 50 | 2024 | 10708 | 1.220 |
Why?
|
| Prospective Studies | 113 | 2022 | 54364 | 1.190 |
Why?
|
| Decision Support Techniques | 9 | 2016 | 1999 | 1.120 |
Why?
|
| Influenza, Human | 12 | 2024 | 1521 | 1.110 |
Why?
|
| Intensive Care Units | 20 | 2021 | 3743 | 1.110 |
Why?
|
| Hypotension | 10 | 2024 | 879 | 1.100 |
Why?
|
| Microscopy, Video | 5 | 2018 | 241 | 1.100 |
Why?
|
| Endothelial Cells | 9 | 2021 | 3550 | 1.090 |
Why?
|
| Influenza Vaccines | 9 | 2024 | 767 | 1.090 |
Why?
|
| Emergency Medicine | 12 | 2021 | 1197 | 1.050 |
Why?
|
| Triage | 12 | 2019 | 984 | 1.030 |
Why?
|
| Shock | 6 | 2020 | 314 | 1.010 |
Why?
|
| Mouth Floor | 8 | 2024 | 38 | 0.990 |
Why?
|
| Heart Arrest | 10 | 2024 | 1513 | 0.940 |
Why?
|
| Severity of Illness Index | 22 | 2022 | 15829 | 0.900 |
Why?
|
| Middle Aged | 183 | 2024 | 220603 | 0.890 |
Why?
|
| Aged | 158 | 2024 | 169092 | 0.870 |
Why?
|
| Bacterial Infections | 2 | 2024 | 1389 | 0.860 |
Why?
|
| Cardiac Output | 3 | 2016 | 831 | 0.850 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 7 | 2019 | 558 | 0.810 |
Why?
|
| Male | 208 | 2024 | 360402 | 0.790 |
Why?
|
| Bacteremia | 5 | 2016 | 977 | 0.790 |
Why?
|
| Health Status Indicators | 5 | 2014 | 970 | 0.780 |
Why?
|
| Humans | 301 | 2024 | 760740 | 0.780 |
Why?
|
| Oxygen | 17 | 2024 | 4226 | 0.770 |
Why?
|
| Critical Care | 11 | 2023 | 2691 | 0.770 |
Why?
|
| Plasma | 1 | 2024 | 586 | 0.730 |
Why?
|
| Female | 204 | 2024 | 392203 | 0.720 |
Why?
|
| Vasoconstrictor Agents | 9 | 2023 | 654 | 0.720 |
Why?
|
| Emergency Medical Services | 7 | 2021 | 1921 | 0.700 |
Why?
|
| C-Reactive Protein | 8 | 2022 | 3820 | 0.690 |
Why?
|
| Regional Blood Flow | 5 | 2017 | 1496 | 0.690 |
Why?
|
| Fever | 2 | 2018 | 1618 | 0.690 |
Why?
|
| Wounds and Injuries | 6 | 2024 | 2492 | 0.680 |
Why?
|
| Risk Assessment | 24 | 2021 | 23974 | 0.670 |
Why?
|
| Outpatients | 5 | 2022 | 1596 | 0.650 |
Why?
|
| Adult | 127 | 2024 | 220995 | 0.650 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2024 | 992 | 0.640 |
Why?
|
| Blood Coagulation Disorders | 2 | 2020 | 350 | 0.630 |
Why?
|
| Appendicitis | 4 | 2022 | 675 | 0.630 |
Why?
|
| Lipocalins | 2 | 2010 | 161 | 0.620 |
Why?
|
| Thrombelastography | 1 | 2020 | 187 | 0.610 |
Why?
|
| Endothelium, Vascular | 8 | 2024 | 4433 | 0.610 |
Why?
|
| Aged, 80 and over | 58 | 2024 | 58919 | 0.600 |
Why?
|
| Diabetes Mellitus | 5 | 2017 | 5838 | 0.600 |
Why?
|
| Diabetes Complications | 2 | 2017 | 1315 | 0.590 |
Why?
|
| Point-of-Care Systems | 5 | 2014 | 1213 | 0.570 |
Why?
|
| Leukocytes | 3 | 2019 | 2024 | 0.550 |
Why?
|
| Vital Signs | 4 | 2017 | 144 | 0.550 |
Why?
|
| Virus Diseases | 2 | 2024 | 718 | 0.540 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 219 | 0.540 |
Why?
|
| Logistic Models | 24 | 2021 | 13248 | 0.540 |
Why?
|
| Patient Admission | 7 | 2015 | 1365 | 0.540 |
Why?
|
| Acute Kidney Injury | 5 | 2023 | 1923 | 0.540 |
Why?
|
| Clinical Protocols | 10 | 2024 | 1436 | 0.540 |
Why?
|
| Length of Stay | 18 | 2021 | 6418 | 0.530 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2017 | 1171 | 0.530 |
Why?
|
| Predictive Value of Tests | 26 | 2019 | 15250 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 12 | 2022 | 7403 | 0.520 |
Why?
|
| Calcitonin | 1 | 2017 | 329 | 0.510 |
Why?
|
| Comorbidity | 18 | 2019 | 10507 | 0.510 |
Why?
|
| Sensitivity and Specificity | 22 | 2018 | 14649 | 0.500 |
Why?
|
| Emergency Treatment | 6 | 2013 | 495 | 0.490 |
Why?
|
| Endotoxemia | 3 | 2018 | 196 | 0.480 |
Why?
|
| Sodium Chloride | 2 | 2014 | 586 | 0.470 |
Why?
|
| Lactates | 3 | 2013 | 404 | 0.460 |
Why?
|
| Hospital Units | 2 | 2015 | 142 | 0.450 |
Why?
|
| Hospitals, Urban | 8 | 2019 | 500 | 0.440 |
Why?
|
| United States | 62 | 2024 | 72292 | 0.440 |
Why?
|
| Consensus | 5 | 2021 | 3117 | 0.420 |
Why?
|
| Prognosis | 24 | 2024 | 29601 | 0.410 |
Why?
|
| Patient Discharge | 9 | 2021 | 3442 | 0.400 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2024 | 410 | 0.400 |
Why?
|
| Acetylcysteine | 1 | 2013 | 260 | 0.390 |
Why?
|
| Calcium Channel Blockers | 1 | 2015 | 694 | 0.390 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2016 | 739 | 0.390 |
Why?
|
| Patient Positioning | 1 | 2014 | 326 | 0.390 |
Why?
|
| Hospitals, University | 7 | 2016 | 565 | 0.390 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2024 | 447 | 0.380 |
Why?
|
| Protein C | 2 | 2009 | 133 | 0.370 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 1388 | 0.370 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2013 | 277 | 0.370 |
Why?
|
| Judgment | 2 | 2019 | 272 | 0.370 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 3088 | 0.360 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 3209 | 0.360 |
Why?
|
| Goals | 1 | 2016 | 708 | 0.360 |
Why?
|
| Hyperoxia | 4 | 2018 | 258 | 0.360 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 1411 | 0.350 |
Why?
|
| Chest Pain | 7 | 2015 | 1091 | 0.350 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 1009 | 0.350 |
Why?
|
| Systems Biology | 1 | 2013 | 481 | 0.340 |
Why?
|
| Contrast Media | 2 | 2013 | 5305 | 0.340 |
Why?
|
| Carbon Dioxide | 2 | 2018 | 1148 | 0.340 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 1884 | 0.330 |
Why?
|
| Critical Pathways | 3 | 2019 | 474 | 0.330 |
Why?
|
| Cohort Studies | 35 | 2024 | 41464 | 0.330 |
Why?
|
| Hyperglycemia | 4 | 2012 | 1375 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1241 | 0.330 |
Why?
|
| Receptor, TIE-2 | 2 | 2021 | 176 | 0.330 |
Why?
|
| Leg | 1 | 2014 | 1087 | 0.330 |
Why?
|
| Blood Coagulation Tests | 1 | 2010 | 271 | 0.320 |
Why?
|
| Confidence Intervals | 7 | 2014 | 2925 | 0.320 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 365 | 0.320 |
Why?
|
| Case-Control Studies | 18 | 2024 | 22153 | 0.320 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 83 | 0.310 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 1866 | 0.310 |
Why?
|
| APACHE | 4 | 2017 | 267 | 0.310 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 285 | 0.310 |
Why?
|
| Hydroxychloroquine | 3 | 2022 | 426 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2019 | 20556 | 0.300 |
Why?
|
| Interleukin-1 | 2 | 2009 | 1248 | 0.300 |
Why?
|
| Erythrocytes | 5 | 2020 | 2410 | 0.300 |
Why?
|
| Acid-Base Equilibrium | 1 | 2008 | 181 | 0.300 |
Why?
|
| Vaccination | 11 | 2024 | 3370 | 0.290 |
Why?
|
| Respiration | 1 | 2014 | 1656 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8998 | 0.290 |
Why?
|
| Dermis | 1 | 2009 | 202 | 0.290 |
Why?
|
| Medical Staff, Hospital | 3 | 2019 | 601 | 0.290 |
Why?
|
| Dyspnea | 6 | 2015 | 1347 | 0.290 |
Why?
|
| Hypovolemia | 1 | 2007 | 48 | 0.290 |
Why?
|
| Angiopoietin-2 | 6 | 2021 | 172 | 0.290 |
Why?
|
| Area Under Curve | 8 | 2018 | 1635 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 4512 | 0.280 |
Why?
|
| Pneumonia | 2 | 2011 | 2143 | 0.270 |
Why?
|
| Appendectomy | 3 | 2022 | 433 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7390 | 0.270 |
Why?
|
| Monitoring, Physiologic | 4 | 2021 | 1780 | 0.270 |
Why?
|
| Community-Acquired Infections | 4 | 2020 | 469 | 0.270 |
Why?
|
| Malpractice | 2 | 2023 | 556 | 0.270 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2007 | 113 | 0.260 |
Why?
|
| Cholecalciferol | 2 | 2021 | 553 | 0.250 |
Why?
|
| Inflammation | 5 | 2019 | 10759 | 0.250 |
Why?
|
| Odds Ratio | 9 | 2021 | 9644 | 0.250 |
Why?
|
| Kidney Diseases | 2 | 2013 | 2090 | 0.250 |
Why?
|
| Neoplasms | 8 | 2022 | 22131 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 2164 | 0.240 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 3149 | 0.240 |
Why?
|
| E-Selectin | 3 | 2013 | 577 | 0.240 |
Why?
|
| Insulin | 2 | 2017 | 6593 | 0.240 |
Why?
|
| Risk Factors | 28 | 2020 | 74128 | 0.230 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2019 | 1723 | 0.230 |
Why?
|
| Interleukin-6 | 6 | 2019 | 3205 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6473 | 0.230 |
Why?
|
| ROC Curve | 9 | 2017 | 3575 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2016 | 3410 | 0.230 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1788 | 0.230 |
Why?
|
| Blood Preservation | 2 | 2016 | 169 | 0.220 |
Why?
|
| Respiration, Artificial | 6 | 2023 | 2630 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2022 | 3492 | 0.220 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2011 | 691 | 0.220 |
Why?
|
| Time Factors | 22 | 2023 | 39908 | 0.220 |
Why?
|
| Patient Transfer | 1 | 2010 | 793 | 0.220 |
Why?
|
| Adenosine Triphosphate | 4 | 2019 | 1988 | 0.210 |
Why?
|
| RNA, Messenger | 9 | 2023 | 12759 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2013 | 1128 | 0.210 |
Why?
|
| Immunocompetence | 2 | 2022 | 138 | 0.210 |
Why?
|
| Communicable Diseases | 2 | 2014 | 871 | 0.210 |
Why?
|
| Watchful Waiting | 2 | 2018 | 491 | 0.210 |
Why?
|
| Multivariate Analysis | 9 | 2014 | 12043 | 0.210 |
Why?
|
| Vaccines, Synthetic | 5 | 2022 | 612 | 0.200 |
Why?
|
| Oxazines | 1 | 2024 | 349 | 0.200 |
Why?
|
| Retrospective Studies | 33 | 2023 | 80583 | 0.200 |
Why?
|
| Enoxaparin | 1 | 2005 | 391 | 0.200 |
Why?
|
| Boston | 8 | 2024 | 9313 | 0.200 |
Why?
|
| Disease Progression | 3 | 2021 | 13495 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2008 | 1723 | 0.200 |
Why?
|
| Leptin | 1 | 2010 | 1595 | 0.200 |
Why?
|
| Age Factors | 11 | 2015 | 18381 | 0.200 |
Why?
|
| Ambulatory Care | 2 | 2020 | 2768 | 0.190 |
Why?
|
| Laryngoscopes | 1 | 2023 | 146 | 0.190 |
Why?
|
| Telemetry | 2 | 2014 | 199 | 0.190 |
Why?
|
| Morpholines | 1 | 2024 | 581 | 0.190 |
Why?
|
| Syndecan-1 | 2 | 2019 | 163 | 0.190 |
Why?
|
| Disease Outbreaks | 2 | 2010 | 1748 | 0.190 |
Why?
|
| Acute Coronary Syndrome | 5 | 2015 | 2190 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 149 | 0.190 |
Why?
|
| Unnecessary Procedures | 2 | 2015 | 414 | 0.180 |
Why?
|
| Ritonavir | 1 | 2022 | 329 | 0.180 |
Why?
|
| Erythrocyte Transfusion | 3 | 2016 | 568 | 0.180 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12448 | 0.180 |
Why?
|
| Young Adult | 22 | 2024 | 59191 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 4 | 2023 | 1700 | 0.180 |
Why?
|
| Emergencies | 3 | 2021 | 1217 | 0.180 |
Why?
|
| Protective Agents | 1 | 2021 | 150 | 0.180 |
Why?
|
| Pancreatitis | 2 | 2018 | 1097 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 79 | 0.180 |
Why?
|
| Influenza A virus | 1 | 2024 | 458 | 0.180 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 269 | 0.180 |
Why?
|
| Accidental Falls | 2 | 2019 | 1067 | 0.170 |
Why?
|
| Oximetry | 2 | 2021 | 459 | 0.170 |
Why?
|
| Appendix | 1 | 2020 | 109 | 0.170 |
Why?
|
| Adolescent | 22 | 2024 | 88247 | 0.170 |
Why?
|
| Work | 1 | 2020 | 195 | 0.170 |
Why?
|
| Treatment Outcome | 24 | 2024 | 64572 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 368 | 0.160 |
Why?
|
| Intubation, Intratracheal | 2 | 2024 | 1331 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 3245 | 0.160 |
Why?
|
| Solubility | 3 | 2014 | 1089 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 238 | 0.160 |
Why?
|
| Diagnosis, Differential | 8 | 2020 | 12966 | 0.160 |
Why?
|
| Flow Cytometry | 4 | 2017 | 5863 | 0.160 |
Why?
|
| Complement C4b | 2 | 2016 | 125 | 0.160 |
Why?
|
| Lipopolysaccharides | 3 | 2019 | 2202 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 934 | 0.160 |
Why?
|
| Iatrogenic Disease | 2 | 2020 | 538 | 0.160 |
Why?
|
| Fractures, Closed | 1 | 2019 | 88 | 0.160 |
Why?
|
| Age Distribution | 3 | 2014 | 2872 | 0.160 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 7805 | 0.150 |
Why?
|
| Advisory Committees | 3 | 2021 | 787 | 0.150 |
Why?
|
| Acute-Phase Proteins | 2 | 2010 | 250 | 0.150 |
Why?
|
| Receptors, Purinergic | 2 | 2015 | 66 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 5493 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2021 | 72 | 0.150 |
Why?
|
| von Willebrand Factor | 2 | 2019 | 676 | 0.150 |
Why?
|
| Contact Tracing | 1 | 2020 | 271 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2021 | 2218 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2011 | 2778 | 0.150 |
Why?
|
| Pandemics | 10 | 2023 | 8652 | 0.150 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2019 | 150 | 0.150 |
Why?
|
| Rib Fractures | 1 | 2019 | 128 | 0.150 |
Why?
|
| Immunomagnetic Separation | 1 | 2017 | 79 | 0.150 |
Why?
|
| Laryngoscopy | 1 | 2023 | 707 | 0.150 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 1662 | 0.150 |
Why?
|
| Hospital Rapid Response Team | 1 | 2018 | 54 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2012 | 6390 | 0.140 |
Why?
|
| Cytokines | 3 | 2020 | 7373 | 0.140 |
Why?
|
| Carnitine | 1 | 2018 | 252 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 186 | 0.140 |
Why?
|
| Sex Distribution | 3 | 2015 | 2278 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1575 | 0.140 |
Why?
|
| Hemodynamics | 8 | 2023 | 4160 | 0.140 |
Why?
|
| Patient Selection | 4 | 2013 | 4237 | 0.140 |
Why?
|
| Hypercapnia | 1 | 2018 | 261 | 0.140 |
Why?
|
| Cell Size | 1 | 2019 | 624 | 0.140 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2020 | 208 | 0.140 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 54 | 0.140 |
Why?
|
| Acute Disease | 6 | 2022 | 7236 | 0.140 |
Why?
|
| Complement Activation | 2 | 2020 | 445 | 0.140 |
Why?
|
| Endothelium | 1 | 2019 | 764 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2018 | 350 | 0.140 |
Why?
|
| Complement C3a | 1 | 2016 | 66 | 0.140 |
Why?
|
| Complement System Proteins | 1 | 2020 | 734 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 346 | 0.130 |
Why?
|
| Morbidity | 2 | 2013 | 1750 | 0.130 |
Why?
|
| Pulmonary Embolism | 4 | 2015 | 2568 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 777 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2020 | 2635 | 0.130 |
Why?
|
| Trauma Centers | 3 | 2017 | 936 | 0.130 |
Why?
|
| Denmark | 2 | 2016 | 770 | 0.130 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 1936 | 0.130 |
Why?
|
| Blood-Borne Pathogens | 1 | 2016 | 52 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2017 | 4785 | 0.130 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 1302 | 0.130 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 245 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2012 | 10072 | 0.130 |
Why?
|
| Nitric Oxide | 3 | 2020 | 2135 | 0.120 |
Why?
|
| Mitochondria | 3 | 2019 | 3619 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 1303 | 0.120 |
Why?
|
| Hypertension | 1 | 2015 | 8532 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1956 | 0.120 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 2756 | 0.120 |
Why?
|
| Angina Pectoris | 3 | 2013 | 959 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 1386 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2015 | 292 | 0.120 |
Why?
|
| Vitamins | 2 | 2021 | 1635 | 0.120 |
Why?
|
| Lipase | 1 | 2017 | 324 | 0.120 |
Why?
|
| Thrombosis | 2 | 2019 | 2942 | 0.120 |
Why?
|
| Automation | 1 | 2017 | 585 | 0.120 |
Why?
|
| International Classification of Diseases | 2 | 2017 | 912 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 786 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2021 | 23415 | 0.120 |
Why?
|
| Placebos | 1 | 2018 | 1667 | 0.120 |
Why?
|
| Pyridines | 2 | 2024 | 2875 | 0.120 |
Why?
|
| Troponin I | 4 | 2012 | 650 | 0.110 |
Why?
|
| Lifting | 1 | 2014 | 55 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 3798 | 0.110 |
Why?
|
| Analgesics | 1 | 2021 | 1067 | 0.110 |
Why?
|
| Stroke Volume | 3 | 2020 | 5486 | 0.110 |
Why?
|
| Calcium Signaling | 2 | 2015 | 734 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 3680 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 564 | 0.110 |
Why?
|
| Hypothermia, Induced | 1 | 2018 | 754 | 0.110 |
Why?
|
| Early Diagnosis | 3 | 2021 | 1185 | 0.110 |
Why?
|
| Blood | 1 | 2016 | 596 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2017 | 1606 | 0.110 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 60 | 0.110 |
Why?
|
| Iodine Compounds | 1 | 2013 | 28 | 0.110 |
Why?
|
| Isotonic Solutions | 1 | 2013 | 117 | 0.110 |
Why?
|
| Glasgow Coma Scale | 3 | 2013 | 579 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2017 | 486 | 0.110 |
Why?
|
| Influenza B virus | 2 | 2024 | 50 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 2214 | 0.100 |
Why?
|
| Seasons | 3 | 2024 | 1518 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5109 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 70 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2020 | 2977 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 490 | 0.100 |
Why?
|
| Immunoassay | 1 | 2016 | 744 | 0.100 |
Why?
|
| Mass Screening | 1 | 2008 | 5425 | 0.100 |
Why?
|
| Biological Assay | 1 | 2015 | 626 | 0.100 |
Why?
|
| Patients' Rooms | 2 | 2015 | 62 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2112 | 0.100 |
Why?
|
| Observer Variation | 3 | 2014 | 2607 | 0.100 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 122 | 0.100 |
Why?
|
| Blood Pressure | 6 | 2019 | 8473 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2567 | 0.100 |
Why?
|
| Executive Function | 1 | 2021 | 1391 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2022 | 1157 | 0.100 |
Why?
|
| Partial Pressure | 3 | 2018 | 245 | 0.100 |
Why?
|
| Terminal Care | 1 | 2024 | 1755 | 0.100 |
Why?
|
| Purines | 1 | 2015 | 606 | 0.100 |
Why?
|
| Medical Records | 2 | 2015 | 1408 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 239 | 0.100 |
Why?
|
| Health Status | 4 | 2022 | 4076 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2019 | 8619 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1597 | 0.100 |
Why?
|
| Probability | 4 | 2013 | 2475 | 0.100 |
Why?
|
| Incidence | 10 | 2017 | 21339 | 0.100 |
Why?
|
| Heparin | 1 | 2019 | 1632 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2019 | 1835 | 0.090 |
Why?
|
| Hospitals, Teaching | 2 | 2019 | 1155 | 0.090 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2014 | 574 | 0.090 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2010 | 17 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2019 | 2478 | 0.090 |
Why?
|
| Sound Spectrography | 1 | 2011 | 113 | 0.090 |
Why?
|
| Anemia | 1 | 2020 | 1504 | 0.090 |
Why?
|
| Cellulitis | 1 | 2012 | 209 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2011 | 148 | 0.090 |
Why?
|
| Creatinine | 2 | 2021 | 1895 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 677 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 271 | 0.090 |
Why?
|
| Prevalence | 6 | 2015 | 15702 | 0.090 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 1070 | 0.090 |
Why?
|
| Troponin | 1 | 2014 | 502 | 0.090 |
Why?
|
| Body Temperature | 2 | 2010 | 780 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 238 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2252 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 1369 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 20077 | 0.090 |
Why?
|
| Coronary Care Units | 1 | 2011 | 235 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2022 | 350 | 0.080 |
Why?
|
| Syncope, Vasovagal | 1 | 2009 | 38 | 0.080 |
Why?
|
| Survival Rate | 5 | 2017 | 12719 | 0.080 |
Why?
|
| Clinical Competence | 3 | 2019 | 4790 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2017 | 2597 | 0.080 |
Why?
|
| Follow-Up Studies | 8 | 2016 | 39062 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5334 | 0.080 |
Why?
|
| Causality | 2 | 2024 | 1241 | 0.080 |
Why?
|
| Mice, Obese | 1 | 2010 | 418 | 0.080 |
Why?
|
| Serpin E2 | 1 | 2009 | 48 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 10175 | 0.080 |
Why?
|
| Acid-Base Imbalance | 1 | 2009 | 41 | 0.080 |
Why?
|
| Physicians | 2 | 2023 | 4583 | 0.080 |
Why?
|
| Wounds, Stab | 1 | 2009 | 72 | 0.080 |
Why?
|
| Medication Adherence | 2 | 2018 | 2175 | 0.080 |
Why?
|
| Bradycardia | 1 | 2010 | 299 | 0.080 |
Why?
|
| Pain | 3 | 2022 | 5062 | 0.080 |
Why?
|
| Receptors, Leptin | 1 | 2010 | 350 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2545 | 0.080 |
Why?
|
| Earthquakes | 1 | 2011 | 191 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12333 | 0.080 |
Why?
|
| Cecum | 1 | 2009 | 233 | 0.080 |
Why?
|
| Syndrome | 3 | 2022 | 3268 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1550 | 0.080 |
Why?
|
| Peroxidase | 1 | 2011 | 610 | 0.080 |
Why?
|
| Dehydration | 1 | 2009 | 216 | 0.080 |
Why?
|
| Ligation | 1 | 2009 | 446 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 10203 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 2851 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2012 | 743 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 6520 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 876 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2137 | 0.070 |
Why?
|
| Environmental Monitoring | 2 | 2011 | 1460 | 0.070 |
Why?
|
| Decision Making | 2 | 2012 | 3919 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1602 | 0.070 |
Why?
|
| Microvessels | 1 | 2012 | 577 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2019 | 105 | 0.070 |
Why?
|
| Asthma | 2 | 2018 | 6234 | 0.070 |
Why?
|
| Capnography | 1 | 2008 | 91 | 0.070 |
Why?
|
| Environmental Exposure | 2 | 2020 | 4483 | 0.070 |
Why?
|
| Phenotype | 4 | 2024 | 16572 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 22117 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2013 | 1112 | 0.070 |
Why?
|
| Serpins | 1 | 2009 | 247 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2022 | 9310 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 3873 | 0.070 |
Why?
|
| Central Venous Pressure | 3 | 2012 | 79 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 865 | 0.070 |
Why?
|
| Forecasting | 2 | 2011 | 2924 | 0.070 |
Why?
|
| Metabolomics | 1 | 2016 | 1656 | 0.070 |
Why?
|
| Curriculum | 2 | 2019 | 3739 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 793 | 0.070 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 1092 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 146 | 0.070 |
Why?
|
| P-Selectin | 1 | 2009 | 599 | 0.070 |
Why?
|
| Communication | 2 | 2019 | 3851 | 0.070 |
Why?
|
| Monocytes | 2 | 2019 | 2565 | 0.070 |
Why?
|
| Adiponectin | 1 | 2012 | 1107 | 0.070 |
Why?
|
| Echocardiography | 2 | 2020 | 4987 | 0.070 |
Why?
|
| Extremities | 1 | 2011 | 867 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2270 | 0.060 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 724 | 0.060 |
Why?
|
| Heart Failure | 3 | 2020 | 11670 | 0.060 |
Why?
|
| Linear Models | 2 | 2014 | 5866 | 0.060 |
Why?
|
| Knowledge | 1 | 2007 | 177 | 0.060 |
Why?
|
| Jurkat Cells | 2 | 2019 | 740 | 0.060 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 697 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2018 | 5965 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2013 | 1083 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2010 | 1697 | 0.060 |
Why?
|
| Sex Factors | 5 | 2011 | 10549 | 0.060 |
Why?
|
| New Jersey | 1 | 2005 | 295 | 0.060 |
Why?
|
| Bacteria | 1 | 2016 | 2192 | 0.060 |
Why?
|
| Disease Management | 1 | 2016 | 2506 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 2746 | 0.060 |
Why?
|
| Quality of Life | 3 | 2022 | 13359 | 0.060 |
Why?
|
| Risk | 5 | 2017 | 9603 | 0.060 |
Why?
|
| Urea | 1 | 2007 | 443 | 0.060 |
Why?
|
| Physical Examination | 1 | 2011 | 1254 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 1624 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2016 | 1186 | 0.060 |
Why?
|
| Blood Transfusion | 2 | 2014 | 1300 | 0.060 |
Why?
|
| Artifacts | 1 | 2013 | 1910 | 0.060 |
Why?
|
| Calcium | 2 | 2016 | 5717 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 1117 | 0.060 |
Why?
|
| Medicago | 1 | 2023 | 4 | 0.060 |
Why?
|
| Child | 4 | 2022 | 80089 | 0.060 |
Why?
|
| Medicare | 1 | 2022 | 6774 | 0.060 |
Why?
|
| Mice | 9 | 2019 | 81368 | 0.060 |
Why?
|
| Cardiotonic Agents | 3 | 2014 | 539 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 1493 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 3805 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5239 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2011 | 883 | 0.060 |
Why?
|
| Databases, Factual | 6 | 2018 | 7963 | 0.060 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2005 | 127 | 0.060 |
Why?
|
| Health Care Rationing | 1 | 2007 | 436 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2018 | 5878 | 0.050 |
Why?
|
| Cognition | 1 | 2021 | 6988 | 0.050 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 898 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 633 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 3451 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 168 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 1406 | 0.050 |
Why?
|
| Pyridazines | 1 | 2024 | 201 | 0.050 |
Why?
|
| Ambulances | 1 | 2003 | 91 | 0.050 |
Why?
|
| Registries | 3 | 2017 | 8209 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2713 | 0.050 |
Why?
|
| Neutrophils | 1 | 2015 | 3763 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4365 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2012 | 6339 | 0.050 |
Why?
|
| Perfusion | 1 | 2007 | 1373 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2009 | 806 | 0.050 |
Why?
|
| Animals | 12 | 2019 | 168202 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 1683 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 729 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2019 | 1163 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 1276 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 973 | 0.050 |
Why?
|
| Delirium | 1 | 2014 | 1667 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2013 | 4470 | 0.050 |
Why?
|
| Masks | 1 | 2024 | 208 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2014 | 11458 | 0.050 |
Why?
|
| Pulse Therapy, Drug | 1 | 2021 | 37 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2017 | 426 | 0.050 |
Why?
|
| Sulfonic Acids | 1 | 2021 | 103 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 3621 | 0.050 |
Why?
|
| Catheterization | 1 | 2006 | 1428 | 0.050 |
Why?
|
| Self Report | 2 | 2023 | 3727 | 0.050 |
Why?
|
| Workload | 1 | 2007 | 844 | 0.050 |
Why?
|
| Massachusetts | 3 | 2014 | 8835 | 0.050 |
Why?
|
| Annual Reports as Topic | 1 | 2020 | 36 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2022 | 2327 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 573 | 0.050 |
Why?
|
| Fecal Impaction | 1 | 2020 | 32 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 227 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2012 | 3095 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 725 | 0.040 |
Why?
|
| Platelet Count | 1 | 2003 | 780 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 2110 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 27100 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 26065 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2020 | 105 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 857 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2020 | 239 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 5144 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3085 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2015 | 709 | 0.040 |
Why?
|
| Intubation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Heart Rate | 2 | 2009 | 4181 | 0.040 |
Why?
|
| Angiopoietin-1 | 1 | 2019 | 122 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 12942 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5671 | 0.040 |
Why?
|
| Absenteeism | 1 | 2020 | 247 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 398 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 315 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2019 | 67 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 1936 | 0.040 |
Why?
|
| Algorithms | 2 | 2011 | 14024 | 0.040 |
Why?
|
| Immunization | 1 | 2023 | 1217 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3045 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 254 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2010 | 3418 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 483 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 616 | 0.040 |
Why?
|
| International Cooperation | 1 | 2005 | 1422 | 0.040 |
Why?
|
| Urban Population | 1 | 2006 | 2034 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2007 | 6223 | 0.040 |
Why?
|
| Mortality | 2 | 2024 | 2899 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2014 | 3238 | 0.040 |
Why?
|
| Heparitin Sulfate | 1 | 2019 | 223 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2021 | 3546 | 0.040 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 441 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 615 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 1390 | 0.040 |
Why?
|
| Video Recording | 1 | 2023 | 965 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 1049 | 0.040 |
Why?
|
| Cause of Death | 1 | 2008 | 3683 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2018 | 42193 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 983 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5822 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 379 | 0.040 |
Why?
|
| Manikins | 1 | 1999 | 244 | 0.040 |
Why?
|
| Isoprostanes | 1 | 2017 | 21 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 458 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 587 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14388 | 0.040 |
Why?
|
| Biopsy | 1 | 2009 | 6763 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4416 | 0.030 |
Why?
|
| Tumor Necrosis Factors | 1 | 2017 | 107 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2017 | 128 | 0.030 |
Why?
|
| Patient Simulation | 1 | 1999 | 298 | 0.030 |
Why?
|
| Acidosis | 1 | 2018 | 268 | 0.030 |
Why?
|
| Maltose-Binding Proteins | 1 | 2016 | 62 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2019 | 696 | 0.030 |
Why?
|
| New England | 1 | 2019 | 1050 | 0.030 |
Why?
|
| Ketorolac Tromethamine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 858 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3204 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2021 | 1068 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 3415 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 1265 | 0.030 |
Why?
|
| Feedback | 1 | 2019 | 790 | 0.030 |
Why?
|
| Nausea | 1 | 2019 | 679 | 0.030 |
Why?
|
| Sheep | 1 | 2018 | 1436 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2021 | 3269 | 0.030 |
Why?
|
| Documentation | 1 | 2022 | 896 | 0.030 |
Why?
|
| Exercise | 1 | 2012 | 5886 | 0.030 |
Why?
|
| Suramin | 1 | 2015 | 34 | 0.030 |
Why?
|
| Health Facilities | 1 | 2021 | 578 | 0.030 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 288 | 0.030 |
Why?
|
| Blood Cells | 1 | 2017 | 305 | 0.030 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2016 | 150 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 376 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1998 | 991 | 0.030 |
Why?
|
| Aftercare | 1 | 2021 | 913 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2010 | 3426 | 0.030 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2014 | 22 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2023 | 2838 | 0.030 |
Why?
|
| Body Weight | 1 | 2005 | 4615 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 721 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 662 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 271 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 242 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 18220 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 577 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2010 | 18937 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2019 | 615 | 0.030 |
Why?
|
| Erythrocyte Membrane | 1 | 2016 | 439 | 0.030 |
Why?
|
| Complement C3b | 1 | 2014 | 97 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 463 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 476 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 489 | 0.030 |
Why?
|
| Viral Load | 1 | 2023 | 3325 | 0.030 |
Why?
|
| Hemostasis | 1 | 2017 | 469 | 0.030 |
Why?
|
| Observation | 1 | 2015 | 310 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2017 | 624 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 907 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2014 | 169 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 731 | 0.030 |
Why?
|
| Medical Audit | 1 | 2015 | 453 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16968 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2017 | 988 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 315 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 295 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2016 | 771 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2013 | 6826 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 251 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2021 | 1159 | 0.030 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2012 | 13 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 3027 | 0.030 |
Why?
|
| Tachycardia | 1 | 2015 | 597 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 1848 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 905 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1454 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 495 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2189 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2019 | 1888 | 0.020 |
Why?
|
| Time | 1 | 2014 | 545 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15498 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2013 | 518 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2018 | 3088 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 370 | 0.020 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2012 | 130 | 0.020 |
Why?
|
| Health Behavior | 2 | 2014 | 2643 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 9715 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 12934 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1171 | 0.020 |
Why?
|
| Emergency Nursing | 1 | 2011 | 42 | 0.020 |
Why?
|
| Cross Infection | 1 | 2020 | 1422 | 0.020 |
Why?
|
| Blood Component Removal | 1 | 2012 | 132 | 0.020 |
Why?
|
| Myocardium | 1 | 2003 | 4725 | 0.020 |
Why?
|
| Siberia | 1 | 2010 | 30 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2014 | 1045 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2017 | 2358 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4845 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 682 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 574 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 550 | 0.020 |
Why?
|
| Dobutamine | 1 | 2010 | 116 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3333 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2013 | 773 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2022 | 3037 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 933 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 2378 | 0.020 |
Why?
|
| Vibration | 1 | 2011 | 328 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2011 | 281 | 0.020 |
Why?
|
| General Surgery | 1 | 2020 | 1692 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3879 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 1795 | 0.020 |
Why?
|
| Myoglobin | 1 | 2009 | 159 | 0.020 |
Why?
|
| Demography | 1 | 2014 | 1643 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7569 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2020 | 2030 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 202 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2575 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1669 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3901 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5672 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10754 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 982 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 1595 | 0.020 |
Why?
|
| Survivors | 1 | 2019 | 2373 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 7050 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 14599 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2010 | 366 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1999 | 2515 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 1329 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 1748 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2013 | 947 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1896 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3591 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 1812 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1154 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 3593 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 2373 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9526 | 0.020 |
Why?
|
| Students, Medical | 1 | 2019 | 1936 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 1028 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2010 | 697 | 0.020 |
Why?
|
| Swine | 1 | 2016 | 5908 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2013 | 6346 | 0.020 |
Why?
|
| Vitamin D | 1 | 2019 | 3301 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3351 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6305 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 2780 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2023 | 4810 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 3837 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 750 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 4919 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2005 | 206 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2016 | 8311 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2013 | 2481 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2234 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2016 | 4210 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 1023 | 0.010 |
Why?
|
| Body Composition | 1 | 2013 | 2426 | 0.010 |
Why?
|
| Telemedicine | 1 | 2021 | 3051 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 972 | 0.010 |
Why?
|
| Health Services Research | 1 | 2010 | 1808 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 2118 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 9999 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2013 | 2008 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 695 | 0.010 |
Why?
|
| Research Design | 1 | 2018 | 6174 | 0.010 |
Why?
|
| Research | 1 | 2010 | 1977 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 1202 | 0.010 |
Why?
|
| Reference Standards | 1 | 2005 | 1003 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8516 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2092 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2003 | 685 | 0.010 |
Why?
|
| Unconsciousness | 1 | 2003 | 249 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2010 | 1167 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2005 | 664 | 0.010 |
Why?
|
| Rats | 1 | 2016 | 23716 | 0.010 |
Why?
|
| Wound Healing | 1 | 2010 | 2802 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 11069 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2006 | 2422 | 0.010 |
Why?
|
| Computational Biology | 1 | 2010 | 3509 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15609 | 0.010 |
Why?
|
| Kidney | 1 | 2013 | 7044 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3321 | 0.010 |
Why?
|
| Problem Solving | 1 | 1999 | 444 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15577 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 26183 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 1999 | 991 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2007 | 4325 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 4010 | 0.000 |
Why?
|